Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients (EVOLUTION)
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
|
Multiple Myeloma |
Drug: VELCADE (bortezomib) Drug: dexamethasone Drug: cyclophosphamide Drug: Revlimid (lenalidomide) |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase 1/2 Study of VELCADE® (Bortezomib), Dexamethasone, and Revlimid® (Lenalidomide) Versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid Versus VELCADE, Dexamethasone and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma |
- Number of Patients With Combined Complete Response and Very Good Partial Response [ Time Frame: Up to 48 weeks or until disease progression ] [ Designated as safety issue: No ]
Complete response requires negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow.
Very good partial response requires serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level < 100 mg per 24 h
- Number of Patients With Adverse Events (AEs) [ Time Frame: From first dose of study drug through the 30 day post-treatment AE assessment visit ] [ Designated as safety issue: Yes ]Evaluate the safety and tolerability of the combination therapy
- Number of Patients With Overall Response [ Time Frame: Up to 48 weeks or until disease progression ] [ Designated as safety issue: No ]
Overall Response includes complete response and partial response.
Complete response requires negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow.
Partial response requires at least 50% reduction of serum M-protein and reduction in 24-h urinary M-protein by at least 90% or to < 200 mg per 24 hour.
- Number of Patients With Stringent Complete Response Rate [ Time Frame: Up to 48 weeks or until disease progression ] [ Designated as safety issue: No ]Stringent Complete Response is defined as complete response plus normal free light chain (kappa/lambda) ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.
- Number of Patients With Complete Response Rate + Near Complete Response Rate [ Time Frame: Up to 48 weeks or until disease progression ] [ Designated as safety issue: No ]
Complete response requires negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow.
Near Complete response requires positive immunofixation on the serum and/or urine and disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow.
- Duration of Response [ Time Frame: Up to 48 weeks or until disease progression ] [ Designated as safety issue: No ]
Duration of response is the time from date of first documented confirmed response to date of first documented progressive disease. A confirmed response is a response that has been observed on at least two consecutive assessments.
Disease progression requires any one or more of the following: serum m-protein increase >= 25% from nadir(absolute increase >= 0.5 g/dL); Urine m-protein increase >= 25% from nadir(absolute increase >= 200 mg/24 hr), bone marrow plasma cell percentage increase >= 25% from nadir(absolute increase >= 10%), new bone lesion or soft tissue plasmacytomas.
- Time to Disease Progression [ Time Frame: Up to 48 weeks or until disease progression ] [ Designated as safety issue: No ]
Time to disease progression is defined as time from the date of randomization to the date of first documented progressive disease.
Disease progression requires any one or more of the following: serum m-protein increase >= 25% from nadir(absolute increase >= 0.5 g/dL); Urine m-protein increase >= 25% from nadir(absolute increase >= 200 mg/24 hr), bone marrow plasma cell percentage increase >= 25% from nadir(absolute increase >= 10%), new bone lesion or soft tissue plasmacytomas.
- Time to Response [ Time Frame: Up to 48 weeks or until disease response ] [ Designated as safety issue: No ]Time to response is defined as time from date of randomization to the date of the first documentation of a confirmed response. confirmed response is a response that has been observed on at least two consecutive assessments.
- Progression-free Survival [ Time Frame: Up to 48 weeks or until disease progression/death ] [ Designated as safety issue: No ]
Progression-free survival is defined as time from the date of randomization to the date of the first documented progressive disease or death.
Disease progression requires any one or more of the following: serum m-protein increase >= 25% from nadir(absolute increase >= 0.5 g/dL); Urine m-protein increase >= 25% from nadir(absolute increase >= 200 mg/24 hr), bone marrow plasma cell percentage increase >= 25% from nadir(absolute increase >= 10%), new bone lesion or soft tissue plasmacytomas.
- Probability of 1-year Survival [ Time Frame: survival probability at 1 year after randomization ] [ Designated as safety issue: No ]
- Overall Survival [ Time Frame: Up to 48 weeks or until death ] [ Designated as safety issue: No ]Overall survival is defined as time from the date of randomization to the date of death
| Enrollment: | 158 |
| Study Start Date: | August 2007 |
| Study Completion Date: | November 2010 |
| Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: VDR
VELCADE (bortezomib), dexamethasone, and Revlimid (lenalidomide)
|
Drug: VELCADE (bortezomib)
bortezomib 1.3 mg/m^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).
Drug: dexamethasone
dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop
Drug: Revlimid (lenalidomide)
lenalidomide 25 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDR arm) lenalidomide 15 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDCR arm) |
|
Experimental: VDCR
VELCADE (bortezomib), dexamethasone, cyclophosphamide, Revlimid (lenalidomide)
|
Drug: VELCADE (bortezomib)
bortezomib 1.3 mg/m^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).
Drug: dexamethasone
dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop
Drug: cyclophosphamide
cyclophosphamide 500 mg/m^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop
Drug: Revlimid (lenalidomide)
lenalidomide 25 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDR arm) lenalidomide 15 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDCR arm) |
|
Experimental: VDC
VELCADE (bortezomib), dexamethasone, cyclophosphamide
|
Drug: VELCADE (bortezomib)
bortezomib 1.3 mg/m^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).
Drug: dexamethasone
dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop
Drug: cyclophosphamide
cyclophosphamide 500 mg/m^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop
|
|
Experimental: VDC-mod
Modified dosing of VELCADE (bortezomib), dexamethasone, cyclophosphamide
|
Drug: VELCADE (bortezomib)
bortezomib 1.3 mg/m^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).
Drug: dexamethasone
dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop
Drug: cyclophosphamide
cyclophosphamide 500 mg/m^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop
|
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Voluntary written informed consent
- Male or female subject 18 years of age or older
- A Karnofsky Performance Status score of ≥50% (Eastern Cooperative Oncology Group Performance Status score ≤2)
- Subjects must have symptomatic myeloma or asymptomatic myeloma with myeloma-related organ damage
- Diagnosed Multiple myeloma
- Subjects must have measurable disease requiring systemic therapy
- Subjects must not have been treated previously with any systemic therapy for multiple myeloma
- Two weeks must have elapsed since the date of the last radiotherapy treatment
- Women of childbearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 to 14 days prior to therapy and repeated within 24 hours before starting study drug. They must commit to continued abstinence from heterosexual intercourse or begin 2 acceptable methods of birth control (1 highly effective method and 1 additional effective method) used at the same time, beginning at least 4 weeks before initiation of Revlimid treatment. Women must also agree to ongoing pregnancy testing
- Men must agree to not father a child and agree to use a latex condom during therapy and for 4 weeks after the last dose of study drug, even if they have had a successful vasectomy, if their partner is of childbearing potential
- All subjects must agree to comply with the requirements of the RevAssistSM program
Exclusion Criteria:
- History of allergy to any of the study medications, their analogues, or excipients in the various formulations
- ≥Grade 2 peripheral neuropathy on clinical examination
- Myocardial infarction within 6 months prior to enrollment or New York Heart Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or clinically significant conduction system abnormalities.
- Female subject who is pregnant or breast-feeding
- Clinically relevant active infection or serious comorbid medical conditions
- Any condition, including laboratory abnormalities, that in the opinion of the Investigator places the subject at unacceptable risk if he/she were to participate in the study. This includes but is not limited to serious medical or psychiatric illness likely to interfere with participation in this clinical study
- Active prior malignancy diagnosed or treated within the last 3 years
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00507442
| United States, Colorado | |
| Rocky Mountain Cancer Center | |
| Denver, Colorado, United States, 80218 | |
| United States, Minnesota | |
| Mayo Clinic | |
| Rochester, Minnesota, United States, 55904-0001 | |
| Study Director: | Medical Monitor | Millennium Pharmaceuticals, Inc. |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Millennium Pharmaceuticals, Inc. |
| ClinicalTrials.gov Identifier: | NCT00507442 History of Changes |
| Other Study ID Numbers: | C05008 |
| Study First Received: | July 25, 2007 |
| Results First Received: | November 28, 2011 |
| Last Updated: | July 18, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Millennium Pharmaceuticals, Inc.:
|
Treatment for patients with multiple myeloma who have received no prior treatment |
Additional relevant MeSH terms:
|
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases Dexamethasone acetate |
Dexamethasone Dexamethasone 21-phosphate Lenalidomide Cyclophosphamide Thalidomide Bortezomib BB 1101 Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones |
ClinicalTrials.gov processed this record on September 23, 2016